UK Markets closed

Ambu A/S (0MJF.L)

YHD - YHD Delayed price. Currency in USD
Add to watchlist
2,843,000,064.00+8.48 (+0.00%)
As of 05:07PM EST. Market open.
Full screen
Previous closeN/A
YTD returnN/A
Expense ratio (net)N/A
Last cap gainN/A
Morningstar ratingN/A
Morningstar risk ratingN/A
Sustainability ratingN/A
Net assetsN/A
Beta (5Y monthly)N/A
5y average returnN/A
Holdings turnoverN/A
Last dividendN/A
Average for categoryN/A
Inception dateN/A
  • Globe Newswire

    Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities

    Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Attachment 29_11_2022 Thomas F Schmidt

  • Globe Newswire

    Annual Report 2021/22

    Today, Ambu issues the Annual Report for the financial year 2021/22, including Sustainability Report and Remuneration Report. The reports can be found at Attachments Remuneration Report 2021-22 - Ambu Sustainability Report 2021-2022 - Ambu Ambu-2022-09-30-en Annual Report 2021-22 - Ambu

  • Globe Newswire


    Ambu delivered 4% organic revenue growth for the year 2021/22. Global Endoscopy Solutions (previously named Visualisation) revenues grew organically by 1%, mainly driven by strong growth in the ENT (Ear-Nose-Throat) and urology segments, offset by declining sales in the pulmonology segment, mostly due to high Covid-19 comparables. The Anaesthesia and Patient Monitoring businesses posted positive organic growth of 5% and 13%, respectively, driven by pent-up demand and recovery from the Covid-19 p